Date: 2012-01-25
Type of information:
Product name: AFC-5128
Compound: AFC-5128
Therapeutic area:
Action mechanism: AFC-5128 is a P2X7 antagonist
Company: Affectis Pharmaceuticals (Germany)
Disease: neuropathic pain
multiple sclerosis
Latest news:
Patents: * On January 25, 2012, Affectis Pharmaceuticals AG has announced that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis. The European patent EP2105164 is related to the composition of AFC-5128. The compound is able to cross the blood-brain barrier and target P2X7-expressing CNS-cells such as glia and oligodendrocyte cells which are linked to neurodegenerative processes. Affectis has shown that oral administration of AFC-5128 significantly reduces clinical scores and frequency of relapse in a mouse model of multiple sclerosis. Strong analgesic effects have also been observed in animal models of inflammatory and neuropathic pain. With these efficacy data available, Affectis is on track for filing an IND in 2012 for neuropathic pain and multiple sclerosis.
The granted patent also covers the composition of further P2X7 antagonist compounds. Affectis has filed corresponding patent applications that are being processed in major markets such as the USA, Japan, China, among others.
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
